Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Rummel, Mathias J, Prof Dr, Niederle, Norbert, Prof, Maschmeyer, Georg, Prof, Banat, G Andre, MD, von Grünhagen, Ulrich, MD, Losem, Christoph, MD, Kofahl-Krause, Dorothea, MD, Heil, Gerhard, Prof, Welslau, Manfred, MD, Balser, Christina, MD, Kaiser, Ulrich, Prof, Weidmann, Eckhart, Prof, Dürk, Heinz, MD, PhD, Ballo, Harald, MD, Stauch, Martina, MD, Roller, Fritz, MD, Barth, Juergen, Pharm, Hoelzer, Dieter, Prof, Hinke, Axel, PhD, Brugger, Wolfram, Prof
Published in The Lancet (British edition) (06.04.2013)
Published in The Lancet (British edition) (06.04.2013)
Get full text
Journal Article
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Rummel, Mathias, Prof, Kaiser, Ulrich, Prof, Balser, Christina, MD, Stauch, Martina, MD, Brugger, Wolfram, Prof, Welslau, Manfred, MD, Niederle, Norbert, Prof, Losem, Christoph, MD, Boeck, Hans-Peter, MD, Weidmann, Eckhart, Prof, von Gruenhagen, Ulrich, MD, Mueller, Lothar, MD, Sandherr, Michael, MD, Hahn, Lars, MD, Vereshchagina, Julia, MD, Kauff, Frank, PhD, Blau, Wolfgang, MD, Hinke, Axel, PhD, Barth, Juergen, Pharmacist
Published in The lancet oncology (01.01.2016)
Published in The lancet oncology (01.01.2016)
Get full text
Journal Article